These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

608 related articles for article (PubMed ID: 8636997)

  • 21. Mechanism of plasmid-mediated quinolone resistance.
    Tran JH; Jacoby GA
    Proc Natl Acad Sci U S A; 2002 Apr; 99(8):5638-42. PubMed ID: 11943863
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Identification of ciprofloxacin resistance by SimpleProbe, High Resolution Melt and Pyrosequencing nucleic acid analysis in biothreat agents: Bacillus anthracis, Yersinia pestis and Francisella tularensis.
    Loveless BM; Yermakova A; Christensen DR; Kondig JP; Heine HS; Wasieloski LP; Kulesh DA
    Mol Cell Probes; 2010 Jun; 24(3):154-60. PubMed ID: 20100564
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Gatifloxacin activity against quinolone-resistant gyrase: allele-specific enhancement of bacteriostatic and bactericidal activities by the C-8-methoxy group.
    Lu T; Zhao X; Drlica K
    Antimicrob Agents Chemother; 1999 Dec; 43(12):2969-74. PubMed ID: 10582891
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Topoisomerase IV is a target of quinolones in Escherichia coli.
    Khodursky AB; Zechiedrich EL; Cozzarelli NR
    Proc Natl Acad Sci U S A; 1995 Dec; 92(25):11801-5. PubMed ID: 8524852
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Role of the extended alpha4 domain of Staphylococcus aureus gyrase A protein in determining low sensitivity to quinolones.
    Strahilevitz J; Robicsek A; Hooper DC
    Antimicrob Agents Chemother; 2006 Feb; 50(2):600-6. PubMed ID: 16436716
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Antagonism between bactericidal activities of 4-quinolones and coumarins gives insight into 4-quinolone killing mechanisms.
    Howard BM; Pinney RJ; Smith JT
    Microbios; 1994; 77(311):121-31. PubMed ID: 8152392
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Fluoroquinolone-gyrase-DNA complexes: two modes of drug binding.
    Mustaev A; Malik M; Zhao X; Kurepina N; Luan G; Oppegard LM; Hiasa H; Marks KR; Kerns RJ; Berger JM; Drlica K
    J Biol Chem; 2014 May; 289(18):12300-12. PubMed ID: 24497635
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Targeting of DNA gyrase in Streptococcus pneumoniae by sparfloxacin: selective targeting of gyrase or topoisomerase IV by quinolones.
    Pan XS; Fisher LM
    Antimicrob Agents Chemother; 1997 Feb; 41(2):471-4. PubMed ID: 9021211
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Quinolone mode of action--new aspects.
    Hooper DC
    Drugs; 1993; 45 Suppl 3():8-14. PubMed ID: 7689456
    [TBL] [Abstract][Full Text] [Related]  

  • 30. DNA gyrase, topoisomerase IV, and the 4-quinolones.
    Drlica K; Zhao X
    Microbiol Mol Biol Rev; 1997 Sep; 61(3):377-92. PubMed ID: 9293187
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Selective targeting of topoisomerase IV and DNA gyrase in Staphylococcus aureus: different patterns of quinolone-induced inhibition of DNA synthesis.
    Fournier B; Zhao X; Lu T; Drlica K; Hooper DC
    Antimicrob Agents Chemother; 2000 Aug; 44(8):2160-5. PubMed ID: 10898691
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Mode of action of the new quinolones: new data.
    Hooper DC; Wolfson JS
    Eur J Clin Microbiol Infect Dis; 1991 Apr; 10(4):223-31. PubMed ID: 1650698
    [TBL] [Abstract][Full Text] [Related]  

  • 33. DNA topoisomerase targets of the fluoroquinolones: a strategy for avoiding bacterial resistance.
    Zhao X; Xu C; Domagala J; Drlica K
    Proc Natl Acad Sci U S A; 1997 Dec; 94(25):13991-6. PubMed ID: 9391140
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Alterations in the GyrA subunit of DNA gyrase and the ParC subunit of topoisomerase IV in quinolone-resistant clinical isolates of Klebsiella pneumoniae.
    Deguchi T; Fukuoka A; Yasuda M; Nakano M; Ozeki S; Kanematsu E; Nishino Y; Ishihara S; Ban Y; Kawada Y
    Antimicrob Agents Chemother; 1997 Mar; 41(3):699-701. PubMed ID: 9056017
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mechanism of quinolone mutagenicity in bacteria.
    Gocke E
    Mutat Res; 1991 May; 248(1):135-43. PubMed ID: 1851537
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Sitafloxacin: antimicrobial activity against ciprofloxacin-selected laboratory mutants of Mycoplasma genitalium and inhibitory activity against its DNA gyrase and topoisomerase IV.
    Deguchi T; Kikuchi M; Yasuda M; Ito S
    J Infect Chemother; 2015 Jan; 21(1):74-5. PubMed ID: 25245990
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mutations in topoisomerase IV and DNA gyrase of Staphylococcus aureus: novel pleiotropic effects on quinolone and coumarin activity.
    Fournier B; Hooper DC
    Antimicrob Agents Chemother; 1998 Jan; 42(1):121-8. PubMed ID: 9449271
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The complex of DNA gyrase and quinolone drugs with DNA forms a barrier to transcription by RNA polymerase.
    Willmott CJ; Critchlow SE; Eperon IC; Maxwell A
    J Mol Biol; 1994 Sep; 242(4):351-63. PubMed ID: 7932695
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Interaction of the plasmid-encoded quinolone resistance protein Qnr with Escherichia coli DNA gyrase.
    Tran JH; Jacoby GA; Hooper DC
    Antimicrob Agents Chemother; 2005 Jan; 49(1):118-25. PubMed ID: 15616284
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Norfloxacin-induced DNA gyrase cleavage complexes block Escherichia coli replication forks, causing double-stranded breaks in vivo.
    Pohlhaus JR; Kreuzer KN
    Mol Microbiol; 2005 Jun; 56(6):1416-29. PubMed ID: 15916595
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 31.